Replies to post #218251 on Biotech Values

[dangerM]

ONCS / number of patients who were treated

... the trial info still dates as of Sept 2017 (last update, cf. https://clinicaltrials.gov/ct2/show/NCT02531425) and has some primary completion date of December 2017 + enrollment of max. 10 participants. They first spoke of "to date five patients" in January. So it could be, if they ran the trial a bit longer. However, Oncosec needs an accessible cancer lesion, this is why only some of those very ill patients are eligible at all, cf. eligibility criteria:

- Lesions that are accessible for injection and electroporation, defined as cutaneous or subcutaneous disease.
- At least 2 anatomically distinct lesions accessible for biopsy

This is actually the much bigger question. The current delivery device has "adjustable needles, 1 to 15 mm" (company presentation), any cancer deeper than that is currently out of reach.

IMHO besides Keynote-695 (melanoma) the next most interesting thing will be their coming delivery device (meant to reach deeper) and if it 'delivers' (efficacy, but also pain?).